Nektar Therapeutics (NKTR)
  • Россия
  • Украина

Nektar Therapeutics (NKTR)

Contact Details

455 Mission Bay Blvd S, San Francisco, California, USA 94158-2158
(415) 482-5300
455 Mission Bay Blvd S, San Francisco, California, USA 94158-2158

General Information

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain. In the area of pain, Nektar has a worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation. The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid. Also in the area of pain, NKTR-181, the company`s wholly-owned novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies. Nektar Therapeutics is headquartered in San Francisco, California.

Contact Information

Phone(415) 482-5300
Website 1
Thomson Reuters PermID4295906807


NamePositionTotal Annual CompensationYearPercent Change in Compensation
CEO and President$8,032,9832014125.0%
CFO and Senior VP$3,305,495201498.9%
General Counsel and Senior VP$3,242,8582014119.3%
Chief Scientific Officer and Senior VP$2,139,127201484.5%
Chief Medical Officer and Divisional Executive VP$4,213,2512014

Corporate Data


  • Pharmaceutical Preparation Manufacturing

SIC Industries

  • Pharmaceutical Preparations

Company Size

Sales Volume$231 million


Ticker SymbolNKTR
ExchangeNASDAQ Global Select Market
Year Founded1990


Previous Close15.29
Bid15.21 x 300
Ask15.24 x 900
Day`s Range15.16 - 15.40
52-Week Range9.5 - 17.41
Average Volume (1M)1,311,095
Market Cap.$2,104.34 Million
Last Dividend Amount0
1y Target Price Est.15.57


Period EndingDec. 31, 2015Sep. 30, 2015Jun. 30, 2015Mar. 31, 2015
Total Revenue39,37059,95222,661108,801
Cost of Revenue8,3646,76010,5348,444
Gross Profit31,00653,19212,127100,357
Research Development47,13543,22945,41247,011
Selling General and Administrative13,2359,54410,18410,303
Depreciation and Amortization----
Other Operating Expenses----
Total Operating Expenses68,73459,53366,13065,758
Other Income/Expenses Net----
Earnings Before Interest and Taxes(29,364)419(43,469)43,043
Interest Expense10,9829,4289,2709,221
Income Before Tax(54,100)(8,111)(52,493)34,033
Income Tax Expense3792164213
Minority Interest----
Net Income from Continuing Ops(54,137)(8,203)(52,657)33,820
Discontinued Operations----
Extraordinary Items----
Effect of Accounting Changes----
Other Items----
Net Income(54,137)(8,203)(52,657)33,820
Preferred Stock and Other Adjustments----
Net Income Applicable to Common Shares(54,137)(8,203)(52,657)33,820